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Abstract In this review, we critically evaluate the case–con-
trol studies examining the relationship between rheumatoid
arthritis (RA) and periodontitis, two common chronic inflam-
matory diseases with a similar host-mediated pathogenesis.
We review the “two-hit” periodontitis model that our group
previously proposed, in which we elucidate how a systemic
disease such as RA can potentially exacerbate or initiate
periodontitis. Furthermore, we discuss adjunctive host
modulation therapy, originally developed for periodontitis
(i.e., subantimicrobial-dose doxycycline alone or in combina-
tion with an anti-inflammatory agent), to simultaneously mit-
igate RA and periodontitis. Finally, we review studies describ-
ing periodontal treatment effects on both RA disease activity
measures and systemic inflammation. Current evidence sug-
gests that an association exists between periodontitis and RA.
Well-designedmulticenter longitudinal clinical trials and stud-
ies with sufficient sample sizes are needed to ascertain the
temporal relationship between these two diseases and whether
periodontal treatment can reduce the severity of RA or prevent
its onset.
Keywords Rheumatoid arthritis . Periodontitis . Alveolar
bone loss . Case–control studies . Subantimicrobial dose
doxycycline
Introduction
Periodontitis and rheumatoid arthritis (RA) are two common
chronic inflammatory diseases sharing a similar host-
mediated pathogenesis [1]. Periodontitis is characterized by
soft and hard tissue destruction around teeth, ultimately lead-
ing to tooth loss [2], while RA is characterized by destruction
of cartilage and bone in the joints, mediated by similar bone-
resorptive cytokines and proteinases [1, 3]. Both diseases lead
to significant morbidity, with periodontitis ultimately leading
to tooth loss and loss of masticatory function, and RA leading
to loss of joint function and loss of mobility.
Over the past 15 years, a number of case–control studies
have suggested an association between the two diseases [4,
5••, 6–8, 9••, 10, 11]. Our group recently published a large
case–control study examining the relationship between peri-
odontitis and RA [5••]. By including a rigorously selected
control group and addressing factors that may confound the
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relationship between RA and periodontitis, we endeavored to
mitigate concerns regarding other published case–control
studies. In the current review, we critically evaluate the studies
examining the association between periodontitis and RA.
Furthermore, we update our previously published “two-hit”
periodontitis model, in which we hypothesize how a systemic
disease such as RA can potentially exacerbate or even initiate
periodontitis. We also discuss evidence supporting the poten-
tial use of subantimicrobial-dose doxycycline (SDD), a phar-
macological therapy that is approved by the United States
Food and Drug Administration (FDA) as well as regulatory
agencies in Canada and the European Union, to treat peri-
odontitis as an adjunct to mechanical debridement (scaling
and root planing; SRP) and mitigate both diseases. We exam-
ine recently published periodontal intervention studies and
their effect on RA disease activity measures, and we critically
review their design. Finally, we discuss important questions
that should be answered in future clinical trials, as further
studies are needed to better understand the relationship be-
tween these two diseases.
Clinical Studies Examining the Relationship Between RA
and Periodontitis
In November 2012, a joint workshop was held by the Euro-
pean Federation of Periodontology and the American Acade-
my of Periodontology on periodontitis and its relation to
systemic diseases, including RA. At that time, virtually all of
the studies on the association between RA and periodontitis
that had been published had had fewer than 100 RA patients.
Of those few studies with more than 100 RA patients, de
Pablo et al. [6], had examined NHANES (National Health
and Nutrition Examination Survey) III cross-sectional data,
and had reported that the 103 RA patients in the sample were
more likely than non-RA individuals (n=4,358) to have miss-
ing teeth (mean of 20 vs. 16 missing teeth, p<0.001), to have
periodontitis (odds ratio [OR] 1.82, 95 % confidence interval
[CI]=1.04–3.20) and to be edentulous (OR=2.27, 95 % CI=
1.56–3.31). Periodontitis was defined as the presence of at
least one site with both attachment loss and probing depth≥
4 mm. This study was criticized in the joint workshop [12]
because of the wide confidence intervals after adjusting for
age, sex, race/ethnicity, and smoking, suggesting an imprecise
population estimate.
Kaur et al. [13] published a systematic review, and included
16 case–control and 3 experimental studies that met their
inclusion criteria. Based on ten of these studies that measured
clinical attachment loss [7, 8, 14–21], the overall weighted
mean difference (WMD) between clinical attachment loss in
RA patients versus non-RA patients was 1.17 (95 % CI=
0.43–1.90), suggesting that attachment loss is greater in RA
patients than in non-RA patients. However, only two of these
studies [15, 18] had 100 or more RA participants. Kaur et al.
[13] also reported that increased tooth loss was more common
in individuals with RA than in those without RA, with a
WMD of 2.38 (95 % CI =1.48–3.29), based on seven studies
that met their criteria [7, 8, 15–17, 22, 23]. Only two of these
studies had 100 or more RA patients [15, 22].
In a cross-sectional study not included in the Kaur et al.
systematic review [13], de Smit et al. [11] reported a higher
prevalence of severe periodontitis in RA patients (n=95)
compared to population-based, presumably healthy non-RA
controls (n=420) (27 % vs. 12 %; p <0.001). Severe peri-
odontitis was defined based on the Dutch Periodontal Screen-
ing Index score. RA patients with severe periodontitis also had
significantly higher DAS28 scores (28-joint disease activity
score, a composite measure of RA disease activity) than RA
patients without periodontitis or with moderate periodontitis,
with no difference seen in IgM rheumatoid factor (RF) or anti-
citrullinated protein antibody (ACPA) reactivity.
Shortcomings of these earlier studies included small sam-
ple size, lack of uniformity in defining periodontitis, and the
preferential selection of healthy control groups, the latter
serving as a potential source of bias. In 2014, our group
[5••] published the largest case–control study to examine the
association between periodontitis and RA that included a full-
mouth periodontal examination to determine periodontitis
status. In our study, 287 RA cases and 330 osteoarthritis
(OA) controls were enrolled from four Veterans Administra-
tion Medical Centers and one academic coordinating medical
center. Rather than enrolling healthy or non-arthritic controls,
as in other studies, we enrolled OA patients as a non-
inflammatory arthritis control group, with the expectation that
these patients would be similar demographically to the RA
cases.
Our study was rigorously designed, and addressed short-
comings in previous case–control studies. The comprehensive
periodontal examination was conducted by a single examiner
at each study center, and the examiners were calibrated prior
to study initiation by a single periodontist. Each examiner was
masked with respect to arthritis case status and results of any
other clinical or laboratory evaluations. Probing depths and
gingival recession were determined at six sites per tooth for all
erupted teeth except for third molars. We defined periodontitis
a priori according to the definition of Machtei et al. [24] as the
presence of clinical attachment loss≥6 mm on≥2 teeth and
one or more sites with probing depths≥5 mm. This definition
approximates the severe periodontitis definition based on the
Centers for Disease Control/American Academy of Periodon-
tology (CDC/AAP) classification [25], except that we includ-
ed all six sites per tooth (rather than only the four interprox-
imal sites) to determine the presence or absence of periodon-
titis. Although the CDC/AAP classification includes measure-
ment of six sites per tooth, only the four interproximal sites are
included in the periodontitis case definition, which may
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underestimate the prevalence of disease [26]. By defining
periodontitis in our study as severe periodontitis, the likeli-
hood of a false-positive diagnosis was reduced.
In our study, anti-cyclic citrullinated peptide (CCP)-posi-
tive RA patients were significantly more likely to have peri-
odontitis than OA controls (37.1 % vs. 26.4 %, p=0.006)
[5••]. Based on a multivariable model that accounted for
age, gender, smoking status, HLA-DRB1 shared epitope (ma-
jor histocompatibility antigen associated with RA) positivity,
race/ethnicity, body mass index, oral hygiene with
supragingival plaque as a surrogate, self-reported diabetes
mellitus, marital status, patient-reported oral dryness, and
education level, the anti-CCP-positive RA patients remained
significantly more likely to have periodontitis than controls
(OR=1.59, 95 % CI=1.01–2.49; p=0.043). Relative to RA
patients without periodontitis, those with periodontitis also
were significantly more likely to be positive for RF and had
higher mean serum ACPA and RF concentrations. These
associations were independent of the presence of visible
supragingival plaque.
Regarding tooth loss in our study, there were 786 screening
failures in the RA group and 936 screening failures in the OA
group. Approximately one of every five (21.6 %) RA screen-
ing failures was due to total edentulism, while 17.9 % of the
failures were due to the presence of fewer than nine posterior
teeth, an exclusion criterion. In the OA group, only 8.0 % of
the screening failures were due to total edentulism, while
8.2 % of the screening failures were due to the presence of
too few teeth. These data suggest that tooth loss is more
common in RA patients (relative to the OA control popula-
tion), in agreement with Kaur et al. [13].
In addressing possible mechanisms, our study also exam-
ined the relationship between specific ACPAs and their asso-
ciation with alveolar bone loss [27••]. This focus was based, at
least in part, on prior results from our group showing that
ACPA concentrations were higher among RA patients with
periodontitis [5••] and were positively correlated with the
presence of antibodies to Porphyromonas gingivalis [28], a
major etiologic risk factor associated with periodontitis, and
the only prokaryote known to induce citrullination of RA-
related neoantigens [29]. Following multivariate adjustment,
increased alveolar bone loss was significantly associated with
higher ACPA concentrations. In addition, ACPAs targeting
citrullinated vimentin and histone were significantly increased
in groups with moderate and high alveolar bone loss versus
those with low levels of bone loss, regardless of smoking
status. These data are important, as Harre et al. [30] recently
reported that ACPA binding to citrullinated vimentin en-
hanced osteoclast differentiation into mature osteoclasts, sug-
gesting a link between specific autoantibody production in RA
and alveolar bone loss associated with periodontitis.
A gap in the literature that has been addressed in the past
two years is the examination of an association between RA
and periodontitis in patients with early treatment-naïve RA
[9••, 10]. Similar to a study by Scher and colleagues involving
treatment-naïve RA patients in the U. S., [10], Potikuri et al.
[9••] examined this association in 91 non-smoking RA partic-
ipants compared to 93 healthy controls (age- and sex-matched
non-smoking patients) in India. Probing depths were mea-
sured, and periodontitis was deemed present if the mean
pocket depth in a patient was≥3 mm. The odds of having
periodontitis were 4.28 times higher for patients with RA
(95 % CI=2.35–7.38; p<0.001) compared to healthy controls
(64.8 % vs. 28 %). Antibody titers to RF and ACPA were
significantly higher in RA patients with periodontitis than in
those without periodontitis. This case–control study is impor-
tant for three reasons. First, the association between RA and
periodontitis was observed in non-smoking patients, thereby
eliminating smoking, a strong environmental risk factor for
RA [31–33] and periodontitis [34, 35], as a potential con-
founding variable. Second, since biologics to treat RA can
reduce gingival inflammation and may mitigate periodontitis
[36], this confounder also was removed. Finally, in long-
standing RA, a patient’s removal of supragingival plaque
may be compromised by poor manual dexterity; by examining
patients with early RA (average duration of RA was
25.1 months for ACPA-positive participants), the confound-
ing relationship between heavy plaque accumulations, gingi-
val inflammation, and periodontitis was potentially addressed,
although plaque scores were not reported in this paper. As
discussed earlier [5••], in the study in which we compared
periodontitis prevalence in RA patients versus OA controls,
poor manual dexterity was also likely eliminated as a con-
founding factor by accounting for plaque in the multivariable
model. Thus, these studies [5••, 9••] further strengthen the
evidence supporting an independent association between RA
and periodontitis.
Similarly, Wolff et al. [37] examined the association be-
tween early RA and periodontitis in a small case–control study
conducted in Germany. Only 22 early-RA patients and 22
controls were enrolled. The mean RA disease duration in
this study was 5.9 months. Relative to the healthy controls
(gender-, age- and smoking status-matched), early-RA
patients had a greater number of missing teeth (5.7 vs.
1.9, p=0.002), deeper periodontal pockets (2.9 mm vs.
2.4 mm, p<0.0001), and a higher prevalence of bleeding on
probing (18.6 % vs. 10.5 %, p=0.001) with comparable oral
hygiene between groups.
Dev et al. [38] conducted a cross-sectional study in
which the prevalence of RA was compared in periodon-
titis versus non-periodontitis groups in India. The over-
all prevalence of RA was 4.4 % (37 of 852 participants)
in the periodontitis group (defined based on the Com-
munity Periodontal Index), compared to 1 % prevalence
in the general population. However, the prevalence of
RA was not reported for the control group in this study;
22 Curr Oral Health Rep (2015) 2:20–29
rather, the authors used the general population estimate
of 1 %.
Among other studies published in 2014, Monsarrat et al.
[39] assessed oral health in 74 RA patients, and Khantisopon
et al. [40] did the same in 196 RA participants. However,
neither study had a control group. Finally, in an Indonesian
study, Susanto et al. [41] examined 75 RA patients and 75
controls, and found no difference in periodontitis prevalence
between the two groups, although the RA participants had less
healthy pocket epithelium versus controls based on the peri-
odontal epithelial surface area score. However, the control
group had an extremely high prevalence of moderate to severe
periodontitis (69 %), which likely precluded detection of any
differences relative to the RA group (prevalence=71 %).
Periodontal Host Modulation Therapy to Simultaneously
Mitigate RA and Periodontitis
One obvious pathologic pathway common to both chronic
periodontitis and RA is the excessive degradation of
collagen-rich tissues: gingiva, periodontal ligament, and alve-
olar bone in periodontitis; and bone, cartilage, and other
periarticular tissues in RA. The essential involvement of a
unique category of host-derived tissue-destructive neutral pro-
teinases in these two diseases, the collagenolytic matrix me-
talloproteinases (MMPs), including MMP-1 (collagenase-1),
MMP-8 (collagenase-2), and MMP-13 (collagenase-3) (plus
several other MMPs targeting this ubiquitous connective tis-
sue molecule, collagen, such as MMP-2/gelatinase A and
MMP-14/membrane-type MMP), has been addressed in sev-
eral reviews [42–45]. In turn, this has led to novel pharmaco-
logical treatment strategies common to both RA and periodon-
titis, including the following:
(i) Collagenase or MMP inhibitors used as adjuncts to con-
ventional antibacterial periodontal treatments (i.e., SRP
to reduce the bacterial burden in the periodontal pocket);
in this regard, SDD (a non-antibiotic tetracycline formu-
lation) is an approved adjunctive treatment for periodon-
titis, and is the first-ever systemically administered MMP
inhibitor drug approved by the FDA for any dental or
medical disease [42, 44]; and
(ii) The same MMP inhibitor, SDD (20 mg doxycycline
twice daily) for periodontitis, was found by O’Dell
et al. [46] to be equally effective as the higher antibiotic
dose of doxycycline (100mg twice daily) in reducing the
severity of early RA in a double-blind placebo-con-
trolled clinical trial, except that the antibiotic-dose doxy-
cycline, as expected, showed more adverse events (AEs)
over the two-year protocol than the SDD treatment,
which was similar to the placebo group with regard to
the incidence of AE.
Of particular interest regarding the similar response of both
periodontitis and RA patients to this anti-MMP strategy, both
diseases also appear to benefit similarly from the combination
of the tetracycline-based MMP inhibitor drug administered
together with anti-inflammatory medications. For example, in
the study by O’Dell et al. [46], the control RA patients were
treated with standard-of-care methotrexate (a potent anti-
inflammatory drug) combined with a placebo daily for two
years. The two experimental groups of RA patients were also
administered methotrexate, but in addition, received either
antibiotic-dose doxycycline or non-antibiotic SDD as MMP
inhibitory agents. The two MMP inhibitor formulations were
substantially more effective in reducing global clinical scores
(American College of Rheumatology 50 % improvement
response, ACR50) of RA disease activity than methotrexate
plus placebo. More specifically, a 50 % improvement in ACR
response was observed in 41.6 % of patients receiving 100 mg
doxycycline twice daily, in 38.9 % of individuals receiving
20 mg doxycycline twice daily, and in 12.5 % of participants
receiving a placebo.
This apparent synergistic effect of the tetracycline-based
MMP inhibitor combined with an anti-inflammatory agent
was predicted by earlier studies on rats with experimental/
adjuvant-induced RA [47, 48] as well as in humans with
chronic periodontitis [49]. In the former, an adjuvant arthritic
rat model demonstrated that a non-steroidal anti-inflammatory
drug (NSAID) such as flurbiprofen only reduced signs of
inflammation of the joints, and did not reduce the destruction
of the collagen-rich tissues, bone and cartilage [47]. In con-
trast, arthritic rats treated only with a tetracycline-based MMP
inhibitor (chemically modified tetracycline [CMT]-1, a non-
antimicrobial tetracycline-based compound) showed de-
creased bone and cartilage destruction but no demonstrable
anti-inflammatory effect. However, when CMT-1 was com-
bined with flurbiprofen, a synergistic reduction in both joint
inflammation and tissue destruction was observed [47].
Ramamurthy et al. [48] identified a mechanism for this syn-
ergistic response: the systemically administered NSAID ap-
peared to increase the local/joint tissue uptake of the tetracy-
cline compound by 116 % (delivered to the tissue from the
circulation) compared to CMT-1 uptake by the arthritic tissues
when this drug was administered alone.
A virtually identical synergistic response was seen in
humans with severe periodontitis requiring surgical interven-
tion. In a study by Lee et al. [49], patients who were admin-
istered a low dose (50 mg once daily) of flurbiprofen showed
no reduction in MMP (collagenase and gelatinase) activity in
gingival tissue extracts surgically excised for therapeutic pur-
poses. In contrast, subjects treated with SDD showed signif-
icant reductions (as expected) in these host-derived
collagenolytic proteinases. However, when the ineffective
NSAID was combined with the effective SDD, a synergistic
effect on MMP reduction was observed. As described above,
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this pattern of response to the combination therapy is consis-
tent with the observations of O’Dell et al. [46] in patients with
RA and in rats with experimental RA [47, 48], and provides
additional evidence that both chronic periodontitis and RA are
mediated by common pathological pathways that are sup-
pressed in both diseases by similar MMP inhibitor therapeutic
strategies.
A “two-hit” model for the link between periodontitis and
systemic diseases, including RA, was proposed by Golub
et al. [50], and a modified version is presented in Fig. 1 (used
with the permission of the Journal of Dental Research, SAGE
Publications). It is currently recognized that both periodontitis
and RA, when sufficiently severe or after sufficient duration of
disease, are associated with systemic inflammation character-
ized by elevated circulating levels of acute-phase proteins—
notably C-reactive protein (CRP)—and other biomarkers and
mediators of inflammation (e.g., interleukin [IL]-6) and tissue
destruction (e.g., MMP-9) [23, 50]. Mechanisms have been
described that would enable each of these chronic inflamma-
tory diseases, via an increase in systemic inflammation, to
initiate or enhance the severity of the other. In this regard,
several clinical trials in patients with chronic periodontitis and
cardiovascular disease [51, 52], local (periodontal) and sys-
temic bone loss (i.e., osteopenic postmenopausal women with
chronic periodontitis [53]), or chronic periodontitis and type 2
diabetes [54] have shown that systemically administered SDD
(as a pleiotropic MMP inhibitor pharmacologic), adjunctive to
nonsurgical mechanical debridement periodontal therapy, can
reduce the levels of these biomarkers/mediators of systemic
inflammation (CRP, IL-6, and MMP-9) and collagenolysis,
and benefit both the oral cavity and the medical condition.
Given the efficacy of SDD as adjunctive therapy for periodon-
titis, one would expect that the two-year SDD regimen, which
reduced the severity of early RA in O’Dell’s clinical trial [46],
would have also reduced the severity of chronic periodontitis
in these RA patients, although this was not part of their study.
Fig. 1 A modified “two-hit” model of induction of severe chronic
periodontitis by local and systemic factors, its relationship to RA, and
their mitigation by periodontal host modulation therapy. The first “Hit”
involves the periodontopathic microbial biofilm and its metabolic
products, such as lipopolysaccharide/endotoxin, inducing a local
inflammatory response characterized by increased production in the
periodontium of, particularly, bone-resorptive cytokines (IL-1, IL-6,
TNF-α) and tissue-destructive proteinases (MMP-8, MMP-9, MMP-13,
and neutrophil elastase). The second “Hit” involves a medical disease
associated with destructive periodontitis (e.g., RA) which, like chronic
periodontitis, can induce systemic inflammation characterized by
elevated levels of acute-phase proteins such as C-reactive protein and
other biomarkers/mediators in the circulation (e.g., IL-1, IL-6, TNF-α,
MMP-8, and MMP-9). “Therapeutic reduction” represents the clinical/
biological response to SDD host modulation therapy, adjunctive to SRP.
“Synergistic therapeutic reduction” represents the response to the
combination of SDD plus an anti-inflammatory drug (e.g.,
flurbiprofen), adjunctive to SRP. This figure is a modification of one
published by us previously [50]
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Clearly, further studies to confirm this hypothesis are
warranted.
In addition to systemically administered SDD, which is
non-antimicrobial but retains its anti-collagenolytic proper-
ties, the use of locally delivered antibacterial doxycycline as
an adjunct to mechanical debridement during periodontal
maintenance may be useful in treating not only periodontitis
[55], but concomitant RA as well. We hypothesize that, since
locally delivered sustained-release doxycycline has been
shown to be effective against Porphyromonas gingivalis
[56], the only known prokaryotic organism that possesses
the peptidylarginine deiminase enzyme involved in the
citrullination process [29, 57], reductions in subgingival
P. gingivalis in response to local doxycycline therapy may
result in less protein citrullination in the periodontium, and
therefore less “spillover” of these proteins—or possibly local-
ly produced ACPA—into the systemic circulation. The reso-
lution of inflammation from the host modulatory effects of
doxycycline may also indirectly alter the composition of the
pathologic biofilm back to a healthy microflora, possibly by
impacting the flow and composition of the gingival crevicular
fluid environment in which the microbial shifts occur [58].
Since antibodies to citrullinated proteins are involved in the
pathogenesis of RA [59], it is conceivable that this local and
systemic host modulatory approach may be useful in treating
RA and chronic periodontitis concurrently.
Effects of Conventional Periodontal Treatment on RA
Disease Activity and Systemic Inflammation
We identified four studies that were conducted prior to 2013
that had reported the effects of periodontal treatment on RA
disease activity and systemic inflammation. These studies, as
well as more recent ones, are summarized in Table 1. Limita-
tions of the earlier studies included extremely small sample
size and different periodontitis case definitions: Al-Katma
et al. [60] diagnosed chronic periodontitis based on the Inter-
national Workshop for a Classification of Periodontal Dis-
eases and Conditions (Armitage criteria) [61], while the
Ribeiro et al. [62] and Pinho et al. [63] studies used the
Machtei et al. classification [24]; the periodontitis case defi-
nition was unspecified for Ortiz et al. [64].
Since mid- 2013, three studies have examined the effects of
periodontal treatment on DAS28, a commonly used compos-
ite measure of RA disease activity [65]. Biyikoğlu et al. [66]
recruited RA patients with chronic periodontitis and system-
ically healthy non-RA chronic periodontitis patients (peri-
odontitis identified using the Armitage criteria [61]). All pa-
tients received SRP (one visit per week for four weeks).
DAS28 was significantly decreased one month after nonsur-
gical periodontal treatment in the RA group and remained
stable for the remaining five months of the study. Study
medication use was maintained throughout the study, imply-
ing that the periodontal treatment, not other RA-specific treat-
ments, likely reduced DAS28 scores. Limitations of this study
included the small samples size, failure to use intent-to-treat
analysis, and the lack of a non-periodontally treated RA group
with periodontitis.
Likewise, Erciyas et al. [67] reported on nonsurgical peri-
odontal treatment effects on DAS28 in a three-month study.
RA patients with moderate to high disease activity (DAS28≥
3.2) and RA patients with low disease activity (DAS28<3.2)
were enrolled; all patients had chronic periodontitis based on
the Armitage criteria [61]. All patients received SRP (one visit
per week for four weeks). Three months after nonsurgical
periodontal treatment, DAS28 levels, serum erythrocyte sed-
imentation rate (ESR), CRP, and tumor necrosis factor
(TNF)-α were statistically significantly lower in both groups.
Of note, reductions in DAS28, ESR, and CRP in the
moderate-to-high disease activity group were greater than
those of the low-disease activity group. These authors report-
ed that no medication changes were undertaken during the
course of the study; thus, the reduction in DAS28 activity
could not be explained by RA-specific treatments alone. Lim-
itations of this study included the small sample size as well as
the lack of a control group (an RA group without any peri-
odontal treatment).
Okada et al. [68] recruited patients with RA and periodon-
titis (based on the Armitage classification [61]) and found that
supragingival scaling at the baseline visit resulted in greater
reductions in DAS28-CRP and serum IgG to P. gingivalis and
citrulline than in the control group. Limitations of this study
included a small sample size and inadequate treatment for
periodontitis (supragingival scaling rather than SRP), thus
likely underestimating the periodontal treatment effect.
All previously published periodontal treatment studies in-
cluded mechanical therapy. No periodontal host modulation
therapy (e.g., systemic SDD or local doxycycline application)
was used. In addition, all earlier studies were small, diagnosed
periodontitis based on different case definitions, had varying
follow-up periods (six weeks [64] to six months [63, 66]), and
had different or unspecified RA durations at baseline. To
confirm the use of SRP alone or in conjunction with periodon-
tal host modulation therapy as effective treatment modalities
for reducing RA disease activity, sufficiently powered multi-
center randomized clinical trials are needed, and these have
not been done. The reader is referred to a recent systematic
review/meta-analysis regarding the periodontal treatment ef-
fects on RA disease activity measures [69•].
Monsarrat et al. [70•] published a paper on the design of a
clinical trial in order to examine the effect of periodontal
treatment on the biological and clinical parameters of RA.
Their proposed study will be an open-label randomized con-
trolled trial including participants with both RA and periodon-
titis. The investigators plan to enroll a total of 40 individuals
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into two arms (intervention group including full-mouth SRP,
followed by systemic antibiotics [amoxicillin or clindamycin,
if allergic to penicillins, for seven days], oral hygiene instruc-
tions, and rinsing with 0.12 % chlorhexidine gluconate for
10 days after periodontal treatment). Patients will be followed
for three months, and the same intervention will then be
applied to the control group. The primary outcome of this
study will be change in DAS28 score. Although the sample
size will again be limited, this trial may provide important
guidance for the design of larger clinical trials to determine
whether periodontal therapy can improve clinical out-
comes and quality of life in patients with active RA.
The authors also plan to use multivariate analysis to
account for center effects and any medication changes.
A major drawback of this study is the use of amoxicillin
or clindamycin adjunctive to SRP. This antimicrobial ap-
proach will likely have limited efficacy, as periodontal
pathogens have been shown to be resistant to these anti-
biotics, and this approach will likely lead to increased
antibiotic resistance in these patients [71].
Conclusions and Future Directions
Numerous case–control studies have demonstrated an associ-
ation between RA and periodontitis. Short-term clinical trials
have shown that nonsurgical periodontal treatment can reduce
RA disease activity and systemic inflammation, although
these studies have had small sample sizes, and studies with
larger sample sizes and longer-term follow-up are needed.
Since SDD as an adjunct to SRP has been shown to effectively
treat periodontitis [42], and to successfully improve the pa-
rameters of early RA [46], we propose inclusion of non-
antimicrobial, systemically administered SDD alone or in
Table 1 Periodontitis Intervention Studies in Rheumatoid Arthritis Patients
Study Number of Patients and Periodontal
Treatment
Design/Duration Main Systemic Findings
Ribeiro et al. [62] RA Control: n=16, OHI+
Supragingival Cleaning
RA Experimental: n=26, OHI+
Supragingival Cleaning+SRP
− Randomization not specified
− 3 months
↓ ESR in experimental group; No change in RF or
HAQ
Al-Katma et al. [60] RA Control: n=12, no treatment
RA Experimental: n=17, OHI+SRP
− Randomized
− No intent-to-treat analysis
(i.e., dropouts not included in
analysis)
− 8 weeks
↓ ESR and DAS28 in experimental group
compared with control group; No change in
swollen or tender joint count, global well-being
or morning stiffness
Pinho et al. [63] RA Control: n=15, no periodontal
treatment
RA Control: n=15, full mouth
extraction, no follow-up visit
RA Experimental: n=15, SRP




No differences at 6 months between RA groups in
ESR or other acute phase reactants or DAS28
Ortiz et al. [64] RA Control: n=20, no periodontal
treatment, half on anti-TNF-α




↓ DAS28, swollen and tender joints, global well-
being, and TNF-α in group receiving
periodontal treatment
Biyikoğlu et al. [66] Non-RA patients: n=15
RA patients: n=15
Both groups received OHI+SRP
− Per protocol analysis, not intent-to-
treat (only 10 RA patients and 12
non-RA patients completed the
study)
− 6 months
↓ DAS28 one month after SRP in RA patients,
maintained at 3 and 6months; ↓CRP onemonth
and three months after SRP; No change in RF,
ESR
Erciyas et al. [67] RA patients with moderate-to-high
DAS28 scores, n=30
RA patients with low DAS28 scores,
n=30
Both groups received OHI+SRP
− 3 months ↓DAS28, ESR, CRP and TNF-α in both groups at
3 months
Okada et al. [68] RA Control: n=29, no periodontal
treatment




Greater ↓ in DAS28-CRP and serum IgG to P.
gingivalis and citrulline in the periodontal
treatment group than in the control group; No
change in swollen or tender joint count, global
well-being, CRP, RF, or anti-CCP antibody
Key: CCP Cyclic citrullinated peptide, CRP C-reactive protein, DAS28 Disease Activity Score (28 joints), ESR Erythrocyte sedimentation rate, HAQ
Health Assessment Questionnaire,OHIOral hygiene instructions, RFRheumatoid factor, SRP Scaling and root planing, TNF-α Tumor necrosis factor-α
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combination with an anti-inflammatory agent and locally
delivered doxycycline (for probing depths 5 mm and
greater) in future clinical trials examining the effect of
periodontal therapy on RA disease activity. All of these
pharmaceutical approaches are adjunctive to SRP. Cus-
tomizing treatment of periodontitis in RA patients based
on their systemic inflammatory status (i.e., personalized
medicine approach) should also be considered [72]. We
hypothesize that the impact of periodontal treatment on
RA may be greater in patients with more systemic inflam-
mation and when SRP is used in combination with
adjunctive periodontal host modulation therapy.
Further longitudinal studies are also needed to address the
temporal relationship between these two diseases. Questions
to address via longitudinal studies and clinical trials include:
Does a diagnosis of periodontitis precede the presence of
serum ACPA and clinical presentation of RA? Is periodontitis
merely another manifestation of RA (i.e., another “joint”)?
Can treatment of periodontitis prevent the onset of clinical RA
in patients at risk for RA or in patients who are already
positive for ACPA? Can periodontal treatment meaningfully
ameliorate the symptoms of RA and reduce RA disease activ-
ity? Lastly, mechanistic studies need to be conducted to better
understand the connection between these two diseases.
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